Influenza virus causes acute respiratory infection in humans, and is a major public health
concern globally. Antibodies play a central role in host protection against influenza virus. We …

Influenza viruses are a continuous threat to human public health because of their ability to
evolve rapidly through genetic drift and reassortment. Three human monoclonal antibodies …

New strategies to prevent and treat influenza virus infections are urgently needed. A recently
discovered class of monoclonal antibodies (mAbs) neutralizing an unprecedented spectrum …

Antibodies are ideal for controlling the influenza A virus, but their effect on newly emerging
strains is unclear. Here, we assessed the neutralization activity of the humanized …

Influenza A virus continuously infects humans and the antigenic shifts of this respiratory virus
enable it to cross the species barrier, threatening public health with the risk of pandemics …

Background Human antibodies that interfere with the biological activity of haemagglutinins
(HAs) of influenza viruses have high potential as an antiviral agent. Methods Human single …

Broadly cross-reactive antibodies (Abs) that recognize conserved epitopes within the
influenza virus hemagglutinin (HA) stalk domain are of particular interest for their potential …

Pandemic influenza A virus (H1N1) 2009 poses a serious public-health challenge
worldwide. To characterize the neutralizing epitopes of this virus, we generated a panel of …

Monoclonal antibodies (MAbs) provide scope for the development of better therapeutics and
diagnostic tools. Herein, we describe the binding and neutralization profile (s) for a panel of …

Seasonal influenza viruses are highly contagious, leading to 290,000–650,000 mortalities
every year globally. Among the influenza viruses, influenza A virus (H3N2) has attracted …